Why Damora Therapeutics, Inc.’s (DMRA) Stock Is Down 8.90%
As of Wednesday, July 22, Damora Therapeutics, Inc.’s DMRA share price has dipped by 8.90%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
Commentary & Analysis
Why Damora Therapeutics, Inc.’s (DMRA) Stock Is Up 5.75%
As of Monday, July 20, Damora Therapeutics, Inc.’s DMRA share price has surged by 5.75%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Damora Therapeutics, Inc.’s (DMRA) Stock Is Up 7.43%
As of Tuesday, July 14, Damora Therapeutics, Inc.’s DMRA share price has surged by 7.43%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Damora Therapeutics, Inc.’s (DMRA) Stock Is Down 6.24%
As of Monday, July 13, Damora Therapeutics, Inc.’s DMRA share price has dipped by 6.24%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Damora Therapeutics, Inc.’s (DMRA) Stock Is Up 6.41%
As of Thursday, July 09, Damora Therapeutics, Inc.’s DMRA share price has surged by 6.41%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | DMRA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,873.7 | $286.3 | 52% |
|
| Shares Out (Mil) | 61.1 | 54.2 | 52% |
|
| Institutional Ownership | 99.7% | 92.8% | 92% |
|
| Float (Mil) | 41.4 | 39.7 | 43% |
|
| Beta | 1.48 | 0.94 | 83% |
|
| Avg Daily Volume (000s) | 301 | 534 | 50% |
|
| Price Change (52-week) |
800.6% | 58.7% | 100% |
|
| Growth | DMRA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (43.2%) | (10.1%) | 8% |
|
| EPS (5yr) | 4.2% | 16.0% | 37 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (26.5%) | (15.6%) | 24% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 4 | 4 | |
| Current EPS | ($0.435) | ($1.893) | ($2.143) | |
| Month Ago EPS | ($0.395) | ($1.755) | ($2.078) | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | ($0.415) | ($1.790) | ($2.105) | |
| Year/Year Chg | 10.4% | (98.8%) | (98.4%) | |
| Financials | DMRA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($263) | ($43) | 5% |
|
| EPS (TTM) | ($9.876) | ($1.400) | 4% |
|
| Operating Cash Flow (TTM) (Mil) | ($45) | ($31) | 10% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $1,503 | $160 | 45% |
|
| Valuation | DMRA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.86 | 2.77 | 77% |
|
| P/E | na | 19.1 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | DMRA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 64.2% | na |
|
| Net Margin | na | (75.9%) | na |
|
| ROA | (94.3%) | (47.3%) | 6% |
|
| ROE | (132.8%) | (55.0%) | 7% |
|
| Liabilities to Assets | 5.1% | 29.6% | 2% |
|
| F-Score | 3 | 2 | 18% |
|
Damora Therapeutics, Inc. did not pass any screens on 8/20/2026.
